ZUBION

Each ml contains:
Buparvaquone. 50 mg (5%)
Excipients. q.s.

Treatment of clinical Theileriosis caused by Theileria annulata.
Managing East Coast Fever caused by Theileria parva.
Controlling high fever associated with acute Theileriosis infection.
Treating animals that show signs of severe protozoan anaemia.
Curative and prophylactic use against Theileria species.

Buparvaquone is a hydroxynaphthoquinone compound structurally related to parvaquone. It acts specifically against the intra-erythrocytic and lymphoid schizont stages of Theileria species (T. annulata and T. parva). The drug interferes with the protozoan's electron transport chain in its mitochondria, effectively blocking ATP production. This disruption halts the parasitic replication cycle and rapidly leads to the death of the protozoa, resolving the clinical signs of Theileriosis in the host animal.

Highly effective against both schizont and piroplasm stages.
Provides rapid clinical response, reducing fever quickly.
Single-shot treatment simplifies management and stress.
Offers excellent bioavailability after intramuscular administration.
Aids in quick recovery of appetite and general health status.

Target Dose: Buparvaquone 2.5 mg/kg body weight.
Inclusion Rate: 1 ml of ZUBION per 20 kg body weight.
Administration: Deep intramuscular injection, preferably in the neck or gluteal muscle. A single dose is usually curative. In severe cases, a second dose may be administered 48-72 hours after the first.

20 ml, 30 ml & 50 m vial

Injection